Oral cannabidiol (CBD) treatment has been suggested to alleviate negative symptoms of autism spectrum disorder (ASD). While many CBD preparations have been studied in randomized clinical trials involving ASD, none have used purified CBD preparations or preparations approved by the U.S. Food and Drug Administration, nor have they focused on low-functioning children with ASD. Previous studies have identified several candidate electrophysiological biomarkers for the cognitive and behavioral disabilities in ASD, with one emerging biomarker being aperiodic neural activity. Here we examined whether periodic (oscillatory) and/or aperiodic electroencephalography (EEG) features are predictive of any symptomatic changes in ASD following pharmacological CBD intervention. To do this, we leveraged resting-state EEG from children with low-functioning ASD (24 boys, aged 7-14 years) using data obtained during a prior double-blind, placebo-controlled, crossover Phase III Clinical Trial (NCT04517799) that investigated using cannabidiol to treat severe behavior problems in children with ASD. Using linear mixed effect models, we found that aperiodic EEG signal features varied directly with 7-COOH-CBD metabolite levels in blood, as evidenced by a larger aperiodic offset (p < 0.001) and decreased aperiodic exponent (p < 0.05) across the scalp. Furthermore, 7-COOH-CBD metabolite levels in blood had a positive association with nonverbal intelligence and visuomotor coordination (p < 0.05). Finally, changes in visuomotor coordination attributed to occipital oscillatory EEG activity were mediated by changes in 7-COOH-CBD metabolite levels in blood, with distinct effects observed for the delta frequency band (p < 0.05). Our analytical results suggest that this daily CBD preparation and administration schedule exerted some benefits, with improvements to cognitive and behavioral abilities in a low-functioning ASD children population. Our findings support the inclusion of resting-state, aperiodic signal features as candidate biomarkers for tracking the clinical impact of CBD treatment, in addition to traditional oscillatory EEG measures, within a neurodevelopmental context.